Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2014 3
2015 30
2016 63
2017 44
2018 46
2019 36
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

180 results
Results by year
Filters applied: . Clear all
Page 1
Counselling framework for moderate-penetrance cancer-susceptibility mutations.
Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, Offit K, Robson ME. Tung N, et al. Nat Rev Clin Oncol. 2016 Sep;13(9):581-8. doi: 10.1038/nrclinonc.2016.90. Epub 2016 Jun 14. Nat Rev Clin Oncol. 2016. PMID: 27296296 Free PMC article. Review.
Hereditary breast and ovarian cancer: new genes in confined pathways.
Nielsen FC, van Overeem Hansen T, Sørensen CS. Nielsen FC, et al. Nat Rev Cancer. 2016 Sep;16(9):599-612. doi: 10.1038/nrc.2016.72. Epub 2016 Aug 12. Nat Rev Cancer. 2016. PMID: 27515922 Review.
Genetic abnormalities in the DNA repair genes BRCA1 and BRCA2 predispose to hereditary breast and ovarian cancer (HBOC). However, only approximately 25% of cases of HBOC can be ascribed to BRCA1 and BRCA2 mutations. Recently, exome sequencing has uncovered substantial locu …
Genetic abnormalities in the DNA repair genes BRCA1 and BRCA2 predispose to hereditary breast and ovarian cancer (HBOC). However, onl …
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. US Preventive Services Task Force, et al. JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987. JAMA. 2019. PMID: 31429903
Regardless of family or personal history, the USPSTF found adequate evidence that the overall harms of risk assessment, genetic counseling, genetic testing, and interventions are small to moderate. CONCLUSIONS AND RECOMMENDATION: The USPSTF recommends that primary care cli …
Regardless of family or personal history, the USPSTF found adequate evidence that the overall harms of risk assessment, genetic couns …
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Nelson HD, et al. JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430. JAMA. 2019. PMID: 31429902
In 8 RCTs (n = 54 651), tamoxifen (relative risk [RR], 0.69 [95% CI, 0.59-0.84]; 4 trials), raloxifene (RR, 0.44 [95% CI, 0.24-0.80]; 2 trials), and aromatase inhibitors (RR, 0.45 [95% CI, 0.26-0.70]; 2 trials) were associated with lower risks of invasive breast cancer com …
In 8 RCTs (n = 54 651), tamoxifen (relative risk [RR], 0.69 [95% CI, 0.59-0.84]; 4 trials), raloxifene (RR, 0.44 [95% CI, 0.24-0.80]; …
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow S. Daly MB, et al. J Natl Compr Canc Netw. 2017 Jan;15(1):9-20. doi: 10.6004/jnccn.2017.0003. J Natl Compr Canc Netw. 2017. PMID: 28040716
The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagno …
The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendatio …
Breast cancer screening of pregnant and breastfeeding women with BRCA mutations.
Carmichael H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S. Carmichael H, et al. Breast Cancer Res Treat. 2017 Apr;162(2):225-230. doi: 10.1007/s10549-017-4122-y. Epub 2017 Jan 30. Breast Cancer Res Treat. 2017. PMID: 28138892 Review.
Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline.
van Os NJ, Roeleveld N, Weemaes CM, Jongmans MC, Janssens GO, Taylor AM, Hoogerbrugge N, Willemsen MA. van Os NJ, et al. Clin Genet. 2016 Aug;90(2):105-17. doi: 10.1111/cge.12710. Epub 2016 Jan 20. Clin Genet. 2016. PMID: 26662178 Review.
Logically, blood relatives may also carry a pathogenic ATM mutation. Female carriers of such a mutation have an increased risk of breast cancer. ...
Logically, blood relatives may also carry a pathogenic ATM mutation. Female carriers of such a mutation have an increased risk of bre …
Cancer Genetic Counseling and Testing in an Era of Rapid Change.
Hooker GW, Clemens KR, Quillin J, Vogel Postula KJ, Summerour P, Nagy R, Buchanan AH. Hooker GW, et al. J Genet Couns. 2017 Dec;26(6):1244-1253. doi: 10.1007/s10897-017-0099-2. Epub 2017 Apr 22. J Genet Couns. 2017. PMID: 28434142
We aimed to assess genetic counselors' perceptions of how their genetic testing-related practices for hereditary breast and/or ovarian cancer (HBOC) changed after these events. ...
We aimed to assess genetic counselors' perceptions of how their genetic testing-related practices for hereditary breast and/or ovaria …
Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, Horick N, Yang S, Shannon KM, Tung N, Ford JM, Lincoln SE, Ellisen LW. Desmond A, et al. JAMA Oncol. 2015 Oct;1(7):943-51. doi: 10.1001/jamaoncol.2015.2690. JAMA Oncol. 2015. PMID: 26270727 Clinical Trial.
Among these and an additional 23 mutation-positive individuals enrolled from our clinics, most of the mutations (92%) were consistent with the spectrum of cancer(s) observed in the patient or family, suggesting that these results are clinically significant. ...Furth …
Among these and an additional 23 mutation-positive individuals enrolled from our clinics, most of the mutations (92%) were consistent with t …
Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH; BRCA TtoT Community of Practice. McCuaig JM, et al. J Med Genet. 2018 Sep;55(9):571-577. doi: 10.1136/jmedgenet-2018-105472. Epub 2018 Jul 24. J Med Genet. 2018. PMID: 30042185 Free PMC article. Review.
This article serves to provide an overview of the recent evolution of genetic assessment for BRCA1/2-associated gynecologic malignancies and outline a Canadian roadmap to facilitate change, improve genetic testing rates, and ultimately improve outcomes for hereditary ovari …
This article serves to provide an overview of the recent evolution of genetic assessment for BRCA1/2-associated gynecologic malignancies and …
180 results
Jump to page
Feedback